Researchers funded by your kindness and generosity have found that a commonly used chemotherapy drug could be effective against an aggressive form of breast cancer called triple negative breast cancer (TNBC), which is often more aggressive and harder to treat than other forms of breast cancer.
It is estimated that the likelihood a person with advanced TNBC will survive for 5 years or more after their diagnosis is half that of people with less aggressive types of breast cancer.
But there could be new hope for the future, thanks to your support. Professor Robert Kerbel and his team based in Toronto, Canada, have discovered a treatment approach that could lead to a more effective way to treat TNBC with the commonly used and inexpensive chemotherapy drug cyclophosphamide.
Cyclophosphamide is a well-known chemotherapy drug that has been shown to work well in lower doses when given metronomically (continuously over a long time and relatively low doses) to children with a rare cancer called rhabdomyosarcoma. Building on this knowledge, the researchers tested different ways of administering this drug to mice with TNBC.
They found that giving cyclophosphamide metronomically at low doses was more effective at slowing tumour growth compared to conventional treatment schedules that use higher doses of the drug or continuous low doses. This suggests that metronomic, low dose chemotherapy may be a better way to treat people with TNBC.
Until recently, treatment for TNBC in the UK has been limited to non-targeted approaches such as chemotherapy, radiation and surgery, but new drugs and combination therapies are currently under review.
Professor Kerbel and his team hope that this new method of using a well-established chemotherapy drug could one day provide a kinder treatment option that could reduce the severity of side effects.
And although their approach has only been tested in mice so far, the team are optimistic that their findings could pave the way for a successful new treatment for this aggressive type of cancer.
Professor Kerbel and his team are now planning to test other combinations of low dose chemotherapy that could improve the effect of immunotherapy in TNBC.
Incredible discoveries like this would not happen without research – and research cannot happen without the support of people like you. If you’re feeling inspired, why not help us make the breakthroughs of the future by donating and starting new cancer cures today?
Donate now & become a Curestarter
Be part of a united effort to stop lives being cut short by cancer.
